MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
November 01, 2022 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its...
MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
September 21, 2022 17:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
September 06, 2022 06:15 ET
|
MannKind
Study supports the dosing regimen that will be pursued in further clinical programsNo serious adverse events or QT prolongation identifiedPlanning underway to discuss results and the ongoing clinical...
MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
MannKind Corporation Reports 2022 Second Quarter Financial Results
August 09, 2022 16:00 ET
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI™ approved by the FDA in May representing the second FDA-approved product using the Technosphere® inhalation platform V-Go® acquired May...
MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
August 02, 2022 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its...
MannKind Corporation to Participate in the BTIG Biotechnology Conference
August 01, 2022 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7
June 03, 2022 10:00 ET
|
MannKind
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for...
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
May 24, 2022 06:00 ET
|
MannKind
Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s Technosphere® inhalation technologyFirst approval of a dry powder inhaled treatment for PAH and PH-ILDManufacturing of Tyvaso...
MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
May 19, 2022 06:00 ET
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...